Oncology

Patients in US counties with the highest medical debt burden had higher odds of stage IV cancer diagnosis and worse survival than those in the lowest-burden counties.

City of Hope’s national clinical trials model can activate a study across a network of 40 sites in 4 states within 90 days, according to Edward Kim, MD, MBA.

ASCO 2026 spotlights metabolic health in cancer care, as GLP-1 obesity drugs show links to lower metastasis and survival gains, needing trials.

In a study, Black and Hispanic parents were largely willing to enroll children in oncology trials, while clinicians cited hardship and gatekeeping as barriers.

Frank McCormick, PhD, FRS, DSc (Hon), discussed his vision for preemptively treating KRAS-driven precancerous lesions, differences between KRAS allele subtypes, and where the field is headed over the next decade.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.

No adverse effects or injuries associated with the presence of particulate matter in 3 lots of injectable cyclophosphamide have been reported to date.

Efficacy findings from the phase 1/2 LIBRETTO-001 and LIBRETTO-021 trials supported the regulatory approval of selpercatinib in RET gene fusion-positive solid tumors.

A primary driver of skyrocketing health care budgets has been the cost of prescription medications, which is particularly true for oncology, as personalized medicine is the standard of care.

A molecular residual disease test identified which patients with resected colorectal liver metastases gained a survival benefit from adjuvant chemotherapy.

ASCO Breakthrough 2026 spotlighted liquid biopsy, biomarkers, AI, and global equity, showing how data-driven precision oncology shapes personalized cancer care worldwide.

ASCO Breakthrough 2026 spotlights AI-driven tumor boards, trial matching, and MRD/ctDNA-guided therapy, signaling faster and more personalized cancer care.

ASCO Breakthrough 2026 spotlights ADCs, CAR-T, ctDNA-guided colorectal care and menin inhibitors driving precision cancer treatment.

INELDA-certified death doula Kim Stravers shares a detailed account of supporting a patient with pancreatic cancer and Lynch syndrome.

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

Kim Stravers, an INELDA-certified death doula and educator, explains how end-of-life doulas provide nonmedical emotional, practical, and relational support to patients with cancer and their families.

The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.

A large real-world analysis found that concurrent GLP-1 receptor agonist use was linked to significantly improved long-term survival and lower rates of irAEs in patients receiving ICIs.

Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

Findings from a cohort study demonstrated that coexposure to a COVID-19 mRNA vaccine within 90 days of anti–PD-(L)1 treatment improved OS in patients with cancer.

The FDA has approved the updated Guardant360 Liquid CDx, a blood-based cancer test combining genomic and epigenomic analysis, across multiple tumors.

See which trials in lung, gastrointestinal, and genitourinary cancers to be on the lookout for at 2026 ASCO.

This episode of The AI Oncology Revolution highlighted the nursing and APP teams and how they are leading the charge in AI implementation.

Cedars-Sinai investigators transitioned hematology-oncology units to progressive care models to improve safety for patients receiving immunotherapy.

A total of 100 RNs successfully completed the full chemotherapy training program during the 2024 and 2025 evaluation periods.